Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing Cohort Interim Data from Atopic Dermatitis Trial Expected to be Announced December 2024 Registration Phase 3 ...

Parents of children with atopic dermatitis (AD, also called eczema) know that the allergic condition can mean a heightened risk of developing food allergies. The desire to prevent food allergies ...

One critical focus for Roivant Sciences is its pipeline. Its success is heavily reliant on products like VTAMA, currently ...

In one study, ChatGPT information on atopic dermatitis received a score of 3.46/5 from physicians assessing its concordance with clinical guidelines. ChatGPT treatment recommendations for atopic ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, announced ...

RAPT Therapeutics has ended its zelnecirnon program following safety concerns raised by the FDA after a severe adverse event ...

The company's FDA-approved drug Sofdra is the first for the common and embarrassing condition of excessive sweating.

As previously reported, JPMorgan analyst Anupam Rama downgraded Rapt Therapeutics (RAPT) to Underweight from Neutral after the company announced the discontinuation of the zelnecirnon program in ...

In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.

RAPT Therapeutics stock falls after halting its zelnecirnon program following FDA clinical hold. Company shifts focus.

The South San Francisco, Calif., biopharmaceutical company in May shut down two trials of zelnecirnon, which was being evaluated as a treatment for asthma and atopic dermatitis.